Suppression of Galectin 1 Protein May Extend Lifespan in Glioblastoma Patients

A group of McGill University (Montreal, Canada) researchers identify proteins that drive cancer stem cells. Their recent results suggest that targeting and suppressing a particular carbohydrate-binding protein called galectin1 could provide a more effective treatment for glioblastoma, in combination with radiation therapy. The results were published online on August 31, 2021 in Cell Reports. The open-access article is titled “Transcriptional Control of Brain Tumor Stem Cells by a Carbohydrate Binding Protein.” Due in part to its resistance to therapy, glioblastoma is the most common and aggressive cancerous brain tumor in adults. It grows rapidly and spreads quickly. While treatments such as surgery, radiation, and chemotherapy can help ease symptoms for a few months, in most cases tumor cells regrow after treatment and the cancer recurs. According to the researchers, no matter how low the weeds are cut, if the roots are not pulled out, the weeds will just grow back.
Login Or Register To Read Full Story